Pharmaceuticals & Medical Devices Bureau of India
Balance Sheet As At 31 March, 2025

	Particulars	Note no.	As at 31 March, 2025 Amount in Rs.	As at 31 March, 2024 Amount in Rs.
I	**Trust funds / corpus**			
	Contribution of CPSUs	**1**	75,00,000	75,00,000
	Reserve and Surplus	**2**	9,06,03,58,589	6,94,87,97,237
	Current Liabilities			
	Trade Payables	**3**	2,86,04,41,973	1,77,21,65,664
	Others Liabilities	**4**	2,61,71,46,955	2,15,15,64,605
	Total		**14,54,54,47,517**	**10,88,00,27,506**
II	**Assets**			
	Non-Current Assets			
	Fixed Assets	**5**		
	(I) Tangible Assets		97,07,39,819	1,37,04,101
	(II) Intangible Assets		1,03,54,775	36,07,626
	(III) Capital Work in Progress (Building)		-	1,02,27,14,002
	Current assets			
	Inventory	**6**	4,35,77,63,706	3,64,29,23,059
	Trade Receivables	**7**	2,95,84,30,345	1,85,25,90,599
	Cash and Cash Equivalents	**8**	5,44,74,89,576	3,41,53,25,481
	Short-Term Loans and Advances	**9**	10,90,24,173	5,01,39,320
	Other Current Assets	**10**	69,16,45,123	87,90,23,318
	Total		**14,54,54,47,517**	**10,88,00,27,506**
	Accompanying Notes Forming Part of Financial Statements	**1 - 35**		

As per our report of even date
For A P R A and Associates LLP
Chartered Accountants
(Firm Registration No.: 011078N/N500064)

For Pharmaceuticals & Medical Devices Bureau of India

Sd/-
CA Arun Kumar Gupta
Designated Partner
Membership No.: 089657

Sd/-
General Manager (F & A)

Sd/-
CEO & Secretary General

Place: New Delhi
Date: 30.12.2025

Pharmaceuticals & Medical Devices Bureau of India
Statement Of Profit And Loss For The Year Ended 31 March 2025

	Particulars	Note no.	Year ended 31 March, 2025	Year ended 31 March, 2024
			Amount in Rs.	Amount in Rs.
	Revenue from operations	11	12,74,11,01,673	9,36,57,79,247
	Other income	12	66,21,04,630	56,58,56,408
	Grant in Aid (General)		1,69,90,19,601	1,10,00,00,000
I	**Total revenue**		**15,10,22,25,904**	**11,03,16,35,655**
	Expenses:			
	Cost of Goods Purchased	13	10,03,07,21,117	7,96,56,70,220
	Change In Inventories (finished goods)	14	(71,48,40,647)	(1,02,99,35,034)
	Employee Benefit Expenses	15	15,86,12,507	14,36,14,776
	Finance Cost	16	3,46,998	3,31,967
	Depreciation and Amortization Expense	5	11,48,15,494	58,70,477
	Other Expenses	17	3,10,87,47,303	1,80,11,23,297
II	**Total expenses**		**12,69,84,02,772**	**8,88,66,75,703**
III	**Profit /(Loss) before tax (I-II)**		**2,40,38,23,133**	**2,14,49,59,952**
IV	Current Tax		29,22,61,780	48,99,40,112
V	**Profit /(Loss) Carried forward to BS (III-IV)**		**2,11,15,61,353**	**1,65,50,19,840**

Accompanying Notes Forming Part of Financial Statements **1 - 35**

As per our report of even date
For A P R A and Associates LLP
Chartered Accountants
(Firm Registration No.: 011078N/N500064)

For Pharmaceuticals & Medical Devices Bureau of India

Sd/-
CA Arun Kumar Gupta
Designated Partner
Membership No.: 089657

Sd/
General Manager (F & A)

Sd/-
CEO & Secretary General

Place: New Delhi
Date: 30.12.2025